---
figid: PMC9069408__gr5
figtitle: 'Impairment of the autophagy–lysosomal pathway in Alzheimer''s diseases:
  Pathogenic mechanisms and therapeutic potential'
organisms:
- Saccharomyces cerevisiae
- Panax ginseng
- Arachis hypogaea
- Hydrastis canadensis
- Drosophila melanogaster
- Caenorhabditis elegans
- Homo sapiens
- Mus musculus
organisms_ner:
- Drosophila melanogaster
pmcid: PMC9069408
filename: gr5.jpg
figlink: /pmc/articles/PMC9069408/figure/fig5/
number: F5
caption: 'Strategies targeting the autophagy–lysosomal pathway for potential AD treatment.
  Targeting of upstream autophagy signaling such as (1) activation of AMPK (metformin,
  resveratrol, berberine) or (2) inhibition of MTORC1 (rapamycin, everolimus, temsirolimus,
  latrepirdine) can promote autophagosomes formation (3) Small molecules that activate
  TFEB (e.g., curcumin analogue C1, HEP14, aspirin, gemfibrozil, Wy14643, cinnamic
  acid, and gypenoside XVII). Not only promote autophagy flux but also enhance lysosome
  functions, which may represent promising anti-AD agents. (4) Strategies through
  direct enhancing lysosomal functions including inhibition of ClC-7 transporter (β-adrenergic
  agonists: isoproterenol, clenbuterol) and acid nanoparticles. Importantly, above
  mentioned small molecule autophagy enhancers have been shown to reduce Aβ and/or
  MAPT/tau aggregates and alleviate memory deficiency in AD animal models, and some
  of them (e.g., metformin) have shown promising results in clinical trials.'
papertitle: 'Impairment of the autophagy–lysosomal pathway in Alzheimer''s diseases:
  Pathogenic mechanisms and therapeutic potential.'
reftext: Wei Zhang, et al. Acta Pharm Sin B. 2022 Mar;12(3):1019-1040.
year: '2022'
doi: 10.1016/j.apsb.2022.01.008
journal_title: Acta Pharmaceutica Sinica. B
journal_nlm_ta: Acta Pharm Sin B
publisher_name: Elsevier
keywords: Alzheimer's disease (AD) | Amyloid beta (Aβ) peptides | MAPT/tau | Autophagy–lysosomal
  pathway | Autophagy enhancers | Autophagy | Mitophagy | Neurodegenerative diseases
automl_pathway: 0.8143846
figid_alias: PMC9069408__F5
figtype: Figure
redirect_from: /figures/PMC9069408__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9069408__gr5.html
  '@type': Dataset
  description: 'Strategies targeting the autophagy–lysosomal pathway for potential
    AD treatment. Targeting of upstream autophagy signaling such as (1) activation
    of AMPK (metformin, resveratrol, berberine) or (2) inhibition of MTORC1 (rapamycin,
    everolimus, temsirolimus, latrepirdine) can promote autophagosomes formation (3)
    Small molecules that activate TFEB (e.g., curcumin analogue C1, HEP14, aspirin,
    gemfibrozil, Wy14643, cinnamic acid, and gypenoside XVII). Not only promote autophagy
    flux but also enhance lysosome functions, which may represent promising anti-AD
    agents. (4) Strategies through direct enhancing lysosomal functions including
    inhibition of ClC-7 transporter (β-adrenergic agonists: isoproterenol, clenbuterol)
    and acid nanoparticles. Importantly, above mentioned small molecule autophagy
    enhancers have been shown to reduce Aβ and/or MAPT/tau aggregates and alleviate
    memory deficiency in AD animal models, and some of them (e.g., metformin) have
    shown promising results in clinical trials.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Crtc
  - SNF4Agamma
  - AMPKalpha
  - Mitf
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
---
